Approximately, 85–90% of hereditary BRCA1-mutation carriers will develop breast cancer [13] and the majority of these cases demonstrate an aggressive breast tumor phenotype—basal-like, triple-negative {ER(−), PR(−) HER2(−)} [14,15], which is associated with a strong stromal reaction. This evidence concerns the gene BRCA1 and breast neoplasm.